

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 17, 2006 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/579,078
				Filing Date	11/5/2004
				First Named Inventor	Hervé GROUX
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket Number	065691-0443

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	B1	2004/0092015 A1	05/13/2004	BONNET et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	B2	EP 1 206 482 B1	09/24/2003	Inst. Pasteur de Lille; CNRS		
	B3	WO 97/42324 A1	11/13/1997	Schering Corporation		
	B4	WO 01/14408 A2	03/01/2001	Inst. Pasteur de Lille; CNRS		A
	B5	WO 02/20558 A2	03/14/2002	Inst. Pasteur de Lille; CNRS		A
	B6	WO 02/092793 A1	11/21/2002	INSERM		A
	B7	WO 2005/000344 A2	01/06/2005	TX-CELL		A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	B8	AKDIS et al., "Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides," Eur. J. Immunol., 2003, 33:2717-2726.		
	B9	BARRAT et al., "In Vitro Generation of Interleukin 10-producing Regulatory CF4 ⁺ T Cells is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)- and Th2-inducing Cytokines," J. Exp. Med., 195 (5), March 4, 2002, pp. 603-616.		
	B10	BONNET et al., "Chemoselective acylation of hydrazinopeptides: a novel and mild method for the derivatization of peptides with sensitive fatty acids," Tetrahedron Letters, 41, 2000, pp. 45-48.		
	B11	CHEN et al., "Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis," Science, vol. 265, August 26, 1994, pp. 1237-1240.		
	B12	FOUSSAT et al., "A Comparative Study between T Regulatory Type 1 and CD4 ⁺ CD25 ⁺ T Cells in the Control of Inflammation," J. Immun., 2003, pp. 5018-5026.		
	B13	GLENN et al., "Transcutaneous immunization: A human vaccine delivery strategy using a patch," Nature Medicine, 6(12), December 2000, pp. 1403-1406.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 17, 2006 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/579,078
				Filing Date	11/5/2004
				First Named Inventor	Hervé GROUX
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	065691-0443
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B14	GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391, February 26, 1998, p. 851.	
	B15	GROUX, Herve," Type 1 T-Regulatory Cells: Their Role in the Control of Immune Response," Transplantation, 75 (9), May 15, 2003, pp. 8S-12S.	
	B16	GROUX et al., "A CD4 ⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," Nature, 389, October 16, 1997, pp. 737-740.	
	B17	HAMMOND et al., "Transcutaneous immunization: T cell responses and boosting of existing immunity," Vaccine, 19, 2001, pp. 2701-2707.	
	B18	KLINGUER et al., "Synthesis of Hydrazinopeptides Using Solid Phase N-Amination, Application to Chemical Ligation," Tetrahedron Letters, 37(40), pp. 7259-7262, 1996.	
	B19	McGUIRK et al., "Pathogen-specific T Regulatory 1 Cells Induced in the Respiratory Tract by a Bacterial Molecule that Stimulates Interleukin 10 Production by Dendritic Cells: A Novel Strategy for Evasion of Protective T Helper Type 1 Responses by <i>Bordetella pertussis</i> ," J. Exp. Med., 195 (2), January 21, 2002, pp. 221-231.	
	B20	MELNYK et al., "Synthesis of lipopeptides using hydrazone chemical ligation," J. Peptide Res., 52, 1998, pp. 180-184.	
	B21	PICHLER et al., "Cellular and Molecular Pathophysiology of Cutaneous Drug Reactions," Am. J. Clin. Dermatol., 2002: 3(4), pp. 229-238.	
	B22	POWRIE et al., "Regulatory Interactions between CD45RB ^{high} and CD45RB ^{low} CD4 ⁺ T Cells Are Important for the Balance between Protective and Pathogenic Cell-mediated Immunity," J. Exp. Med., 179, February 1994, pp. 589-600.	
	B23	ROUAIX et al., "Effect of a lipopeptide formulation on macrophage activation and peptide presentation to T cells," Vaccine, 1994, 12(13), pp. 1209-1214.	
	B24	THIAM et al., "Unrestricted Agonist Activity on Murine and Human Cells of a Lipopeptide Derived from IFN- γ ," Biochem. And Biophys. Res. Comm., 253, 1998, pp. 639-647.	
	B25	WAKKACH et al., "Characterization of Dendritic Cells that Induce Tolerance and T Regulatory 1 Cell Differentiation In Vivo," Immunity, 18, May 2003, pp. 605-617.	
	B26	ZENG et al., "Synthesis of a New Template with a Built-in Adjuvant and Its Use in Constructing Peptide Vaccine Candidates Through Polyoxime Chemistry," J. Peptide Science, 2, 1996, pp. 66-72.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.